Portal hypertension & Cirrhosis (PH&C)

Official journal of @CHESS_liver. #OpenAccess to cutting-edge advances in cirrhosis, IF: 1.8 #hepatology #medicine #liver #healthcare #liverdisease

[CYSL @CYSLnews]

We are pleased the full program for the upcoming 1st annual CYSL meeting at #EASL2026 in Barcelona!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

A crucial clinical distinction: While the FVIII/PC ratio is a key predictor for decompensation, it does not correlate with Portal Vein Thrombosis (PVT). For assessing PVT risk, FVIII activity alone remains the recommended significant predictor.
https://t.co/stiKE0sGkG

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

Using an optimal cutoff of 2.86, Kaplan-Meier analysis shows that patients in the high FVIII/PC group faced a significantly higher risk of further decompensation (16.2% vs. 3.3%), specifically in variceal rebleeding, jaundice, and recurrent ascites.
🔗https://t.co/stiKE0s8v8

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

The FVIII/PC ratio shows enhanced predictive ability within 12 months with an AUC of 0.717. Time-dependent ROC analysis demonstrates its superior accuracy compared to traditional indicators like HVPG, Child-Pugh, and MELD scores for 1-year outcomes.
🔗 https://t.co/stiKE0sGkG

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@j_livercancer @KLCA1999 Nice!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

According to SHAP analysis, the MELD score and the FVIII/PC ratio are the two most influential variables, carrying more prognostic weight than HVPG or Child-Pugh grades in this cohort.
🔗 https://t.co/stiKE0sGkG

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@surgery81261 Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

Now online ! 🩺 Further decompensation events significantly increase mortality in cirrhosis. This study identifies the FVIII/PC ratio as a novel and powerful independent risk factor for predicting these critical events.
https://t.co/stiKE0s8v8

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@HepatomaRes Nice work!

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

New online! Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management https://t.co/eIPEDvCIhf

[Nature Reviews Gastroenterology & Hepatology @NatRevGastroHep]

Our MARCH ISSUE is live! Surgery in HCC, abdominal pain in IBD, WNT–β-catenin signalling in HCC, liver disease and HIV infection, and much more!
https://t.co/o2QuMLtWkT

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@HepatolRes @WileyHealth Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@CMH_journal Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@Rahmeh03 Nice Work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@ASTCT_Journal Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@LiverSaver Nice!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@LTxJournal Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@GIE_Journal @KKadkhodayan @DrHasan_Orlando @ReemSharaiha @BilalMohammadMD @DennisYangMD @SChandanMD @AzharGastro Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@mhenrique028 @JGHofficial Nice work!

[Portal hypertension & Cirrhosis (PH&C) @PHC_Journal]

@ChengHanNg Nice work!